NCT05782023

Brief Summary

The aim of this study is to assess the efficacy of an innovative program of secondary cardiovascular prevention focused on patient empowerment. This program will be characterized by a blended interaction between healthcare workers and the patients: first, a face-to-face first encounter in-hospital for risk factors profiling, followed by remote interactions through a digital approach. The digital intervention is targeted at promoting the adoption and retention of virtuous behavior (e.g. smoking cessation, healthy eating habits, physical exercise, regular assumption of pharmacological therapies), improving cardiovascular risk factors control. Moreover, an exploratory endpoint will be investigated: the reduction of the residual coronary risk.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
400

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Oct 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 18, 2022

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

February 21, 2023

Completed
1 month until next milestone

First Posted

Study publicly available on registry

March 23, 2023

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2025

Completed
Last Updated

March 23, 2023

Status Verified

March 1, 2023

Enrollment Period

2.9 years

First QC Date

February 21, 2023

Last Update Submit

March 22, 2023

Conditions

Keywords

acute myocardial infarctionsecondary preventionatherosclerosishealth empowerment

Outcome Measures

Primary Outcomes (7)

  • Efficacy on measurable risk factors - BMI

    Measured through the changes in the BMI, measured in weight in kilograms divided by the square of height in meters (kg/m2).

    12 months

  • Efficacy on measurable risk factors - systolic blood pressure

    Measured through the changes in the systolic blood pressure, measured in millimetres (mm) of mercury (Hg) (mmHg).

    12 months

  • Efficacy on measurable risk factors - diastolic blood pressure

    Measured through the changes in the diastolic blood pressure, measured in millimetres (mm) of mercury (Hg) (mmHg).

    12 months

  • Efficacy on measurable risk factors - LDL-cholesterol levels

    Measured through the changes in the LDL-cholesterol levels, measured in milligrams per deciliter (mg/dL).

    12 months

  • Efficacy on measurable risk factors - glycemia levels

    Measured through the changes in the glycemia levels, measured in milligrams per deciliter (mg/dL).

    12 months

  • Efficacy on measurable risk factors - glycosylated hemoglobin in diabetic patients

    Measured through the changes in the glycosylated hemoglobin in diabetic patients, measured in percentage (%) of glycosylated hemoglobin over total hemoglobin, or in millimole of glycated hemoglobin per mole of total hemoglobin (mmol/mol).

    12 months

  • Efficacy on measurable risk factors - expired carbon monoxide in smokers

    Measured through the changes in the expired carbon monoxide (CO) in smokers, measured in parts of expired carbon monoxide per million (ppm) per hour (ppm/h), assessed through the Smokerlyzer®.

    12 months

Secondary Outcomes (15)

  • Efficacy on lifestyle changes - physical activity

    12 months

  • Efficacy on lifestyle changes - adherence to a "heart-friendly" diet

    12 months

  • Efficacy on lifestyle changes - smoking reduction or cessation

    12 months

  • Efficacy on lifestyle changes - self-efficacy

    12 months

  • Efficacy on lifestyle changes - Health Locus of Control

    12 months

  • +10 more secondary outcomes

Study Arms (2)

Digital empowerment

EXPERIMENTAL

Usual-care + preventive intervention through digital empowerment

Behavioral: Digital empowerment

Usual care

NO INTERVENTION

Usual-care (cardiologist visit at 1, 3 and 12 months after AMI)

Interventions

The intervention will consist of a minimal interaction face-to-face before hospital discharge for risk factors profiling followed by actions for health empowerment, delivered through an ad-hoc developed web platform, which include: a) periodic delivery of email messages with links to educational, motivational and supportive materials for secondary prevention, b) access to a message box for questions and answers and c) possibility of video-calls with the preventive team.

Digital empowerment

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • STEMI or NSTEMI
  • availability of digital communication devices (smart-phone, tablet or personal computer) and internet access

You may not qualify if:

  • active malignancies (except for skin tumors other than melanoma)
  • life expectancy \<5 years
  • absolute clinical indication to undergo hospital rehabilitation cycles
  • cognitive status undermining digital communication devices use, even after proper training
  • low understanding of Italian language, either oral or written, by clinician's judgement
  • patient not foreseeing to undergo cardiology follow-up at the site

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centro Cardiologico Monzino

Milan, 20138, Italy

RECRUITING

MeSH Terms

Conditions

Atherosclerosis

Condition Hierarchy (Ancestors)

ArteriosclerosisArterial Occlusive DiseasesVascular DiseasesCardiovascular Diseases

Study Officials

  • José P Werba, MD

    Centro Cardiologico Monzino

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

February 21, 2023

First Posted

March 23, 2023

Study Start

October 18, 2022

Primary Completion

September 1, 2025

Study Completion

September 1, 2025

Last Updated

March 23, 2023

Record last verified: 2023-03

Locations